1. KD. Tripathi. Insulin, Oral Hypoglycaemic Drugs and Glucagon. Essentials of medical pharmacology. Seventh edition. 2013. Page – 279.
2. S. R. Sharma and Nalini Sharma. Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective. NCBI; PMC US National Library of Medicine, National Institute of Health. October-December 2008. [Accessed 22nd January 2021] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771994/
3. Manish Maladkar, Girish Rajadhyaksha, N. Venkataswamy, R. S. Hariharan and Sathis R. Lohati. Efficacy, safety, and tolerability of Epalrestat compared to Methylcobalamine in patients with diabetic neuropathy. NCBI; PMC US National Library of Medicine, National Institute of Health. January-March 2009. [Accessed 22nd January 2021] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802362/#:~:text=The%20tolerability%20to%20Epalrestat%20treatment,safety%20parameters%20compared%20to%20Methylcobalamin.
4. Sachin devendrarao shende, Mirza shiraz baig and sudhakar madhukar doifode. Evaluation of Ef?cacy and Safety of Epalrestat (150 mg) Compared to Epalrestat (50 mg) in Patients Suffering from Diabetic Peripheral Neuropathy. ResearchGate. [Revised on April 2018]. [Accessed 22nd January 2021] https://www.researchgate.net/publication/325124796_Evaluation_of_Efficacy_and_Safety_of_Epalrestat_150_mg_Compared_to_Epalrestat_50_mg_in_Patients_Suffering_from_Diabetic_Peripheral_Neuropathy